Brezosiran Cuts Huntington's Protein Up to 83% in Early Trial
ALNY is trading near its 52-week low of $197.81 (14% above the low).
Summary
Alnylam's brezosiran cut mutant huntingtin protein in cerebrospinal fluid by 60–64% at month 3 in the highest dose of a Phase 1b study, with one patient reaching an 83% reduction. The safety profile looked clean through 12 months, with no dose-dependent CSF inflammation, NfL or ventricular increases — the overhang that has dogged prior Huntington's programs. Durability supports twice-yearly dosing, a convenience edge if the drug ever reaches market. The company plans a placebo-controlled pivotal study in 2027, pending regulatory alignment. This is early validation of the CNS RNAi platform, but the real test is clinical slowing of disease progression in the pivotal trial, not biomarker knockdown.
At the time of this announcement, ALNY was trading at $225.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4B. The 52-week trading range was $197.81 to $485.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.